PolyPeptide Group Ltd

PPGN

Equity

ISIN CH1110760852 / Valor 111076085

SIX Swiss Exchange (2024-09-18)

CHF 31.95-0.93%

PolyPeptide Group Ltd
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

PolyPeptide Group Ltd is a Contract Development & Manufacturing Organization (CDMO) that specializes in supporting pharmaceutical and biotech companies with the development and manufacturing of proprietary and generic active pharmaceutical ingredients (API). The company works closely with its clients to provide high-quality services and solutions tailored to their specific needs in the pharmaceutical industry. With a focus on innovation and expertise, PolyPeptide Group Ltd plays a crucial role in helping its clients bring new drugs to market efficiently and effectively.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

PolyPeptide Group Ltd reported a significant increase in revenue for the year ending December 31, 2023. The company's revenue grew to kEUR 320,372, up from kEUR 280,978 in 2022, reflecting a robust performance in its core business operations.

Operating Loss

Despite the increase in revenue, PolyPeptide Group Ltd experienced an operating loss for the year ending December 31, 2023. The company reported an operating result (EBIT) of -kEUR 36,468, a stark contrast to the positive EBIT of kEUR 12,607 in 2022.

Net Loss

PolyPeptide Group Ltd ended the year with a net loss. The result for the year was a loss of kEUR 51,440, compared to a profit of kEUR 7,767 in 2022. This significant downturn was influenced by increased financial expenses and other operating costs.

Earnings Per Share

The earnings per share (EPS) for PolyPeptide Group Ltd also reflected the company's challenging financial year. The basic and diluted EPS for 2023 were both reported at -EUR 1.56, down from EUR 0.24 in 2022.

Comprehensive Income

PolyPeptide Group Ltd's total comprehensive result for the year ending December 31, 2023, was -kEUR 41,294, compared to kEUR 22,953 in 2022. This includes the net loss and other comprehensive income, such as exchange differences on translation of foreign operations and remeasurement gains on defined benefit plans.

Summarized from source with an LLMView Source

Key figures

66.8%1Y

-74.6%3Y

%5Y

Performance

46.9%1Y

65.6%3Y

63.8%5Y

Volatility